Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;8(4):1576-1583.
doi: 10.1002/cam4.2055. Epub 2019 Mar 14.

Serum biomarker panels for the diagnosis of gastric cancer

Dan Wu  1 , Pinglu Zhang  1 , Ji Ma  1 , Jinbo Xu  1 , Li Yang  1 , Weidan Xu  1 , Haifeng Que  1 , Meifen Chen  1 , Hongtao Xu  1
Affiliations

Serum biomarker panels for the diagnosis of gastric cancer

Dan Wu et al. Cancer Med. 2019 Apr.

Abstract

Gastric cancer is a leading cause of mortality due to neoplastic disease. Although early detection of gastric cancers can decrease the mortality rate, it remains a diagnostic challenge because of the lack of effective biomarkers. In this study, fifteen gastric cancer patients and ten healthy subjects were recruited to assess novel serum biomarkers for gastric cancer using antibody microarray technology. ELISA was utilized to validate the antibody array results. As a result, compared to the controls, eleven cytokines were found to be significantly increased in gastric cancer, including interferon gamma receptor 1 (IFNGR1), neurogenic locus notch homolog protein 3 (Notch-3), tumor necrosis factor receptor superfamily member 19L (TNFRSF19L), growth hormone receptor (GHR), signaling lymphocytic activation molecule family 8 (SLAMF8), folate receptor beta (FR-beta), integrin alpha 5, galectin-8, erythropoietin-producing hepatocellular A1 (EphA1), epiregulin, and fibroblast growth factor 12 (FGF-12) with P < 0.05. ELISA validation supported the results of the antibody array. More importantly, most of these eleven cytokines, including IFNGR1, TNFRSF19L, GHR, SLAMF8, FR-beta, and integrin alpha 5 were discovered to be elevated in gastric cancer serum samples for the first time in this study, suggesting that these proteins may serve as novel biomarkers for the early diagnosis and prognosis determination of gastric cancer.

Keywords: antibody array; biomarkers; gastric cancer; serum.

PubMed Disclaimer

Conflict of interest statement

The authors declare that no conflicts of interest exist.

Figures

Figure 1
Figure 1
Scatter plots of differential protein levels. The levels of eleven proteins differentially expressed between gastric cancer and the control samples were detected by antibody array are shown by scatter plots with mean lines and standard deviation lines. Control group, n = 20; Gastric cancer, n = 20
Figure 2
Figure 2
The antibody array profiles. The locations of differentially expressed proteins in the antibody array profiles are marked by blue rectangles. The levels of cytokines are shown by their fluorescence intensity which is proportional to the levels of expression
Figure 3
Figure 3
Unsupervised‐hierarchical cluster analysis. The unsupervised‐hierarchical cluster analysis accurately distinguished gastric cancer from controls, confirming differences in the expression of the eleven proteins between gastric cancer and control. Green indicates low levels of the proteins, black for median levels, and red for high levels. GC, gastric cancer; HC, healthy control
Figure 4
Figure 4
The ELISA results of six differentially expressed proteins. ELISA results of six differentially expressed proteins are shown by scatter plots with mean lines and standard deviation lines. The statistical analysis of these proteins between gastric cancer and control was performed by Mann‐Whitney U test analysis. Control group, n = 20; Gastric cancer, n = 20
See this image and copyright information in PMC

References

    1. Hartgrink HH, Jansen E, van Grieken N, van de Velde C. Gastric cancer. The Lancet. 2009;374:477‐490. - PMC - PubMed
    1. Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut. 2015;64:1650‐1668. - PMC - PubMed
    1. González CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012;130:745‐753. - PubMed
    1. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72‐4 in gastric cancer with peritoneal dissemination. Gastric Cancer. 2012;15:154‐161. - PubMed
    1. Li Y, Yang Y, Lu M, Shen L. Predictive value of serum CEA, CA19‐9 and CA724 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011;58:2166‐2170. - PubMed

Publication types

Substances